Prelude Capital Management’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-32,308
| Closed | -$77K | – | 751 |
|
|
2020
Q3 | $77K | Buy |
+32,308
| New | +$77K | ﹤0.01% | 758 |
|
|
2018
Q4 | – | Sell |
-47,400
| Closed | -$294K | – | 1357 |
|
|
2018
Q3 | $294K | Sell |
47,400
-11,479
| -19% | -$71.2K | 0.02% | 455 |
|
|
2018
Q2 | $266K | Buy |
58,879
+1,579
| +3% | +$7.13K | 0.02% | 545 |
|
|
2018
Q1 | $264K | Buy |
57,300
+14,924
| +35% | +$68.8K | 0.02% | 542 |
|
|
2017
Q4 | $136K | Buy |
42,376
+3,376
| +9% | +$10.8K | 0.01% | 629 |
|
|
2017
Q3 | $120K | Buy |
39,000
+3,853
| +11% | +$11.9K | 0.01% | 752 |
|
|
2017
Q2 | $130K | Buy |
35,147
+2,451
| +7% | +$9.07K | 0.01% | 640 |
|
|
2017
Q1 | $160K | Buy |
32,696
+2,696
| +9% | +$13.2K | 0.02% | 593 |
|
|
2016
Q4 | $154K | Buy |
30,000
+3,671
| +14% | +$18.8K | 0.02% | 638 |
|
|
2016
Q3 | $191K | Buy |
26,329
+8,229
| +45% | +$59.7K | 0.02% | 530 |
|
|
2016
Q2 | $108K | Buy |
18,100
+4,905
| +37% | +$29.3K | 0.02% | 681 |
|
|
2016
Q1 | $107K | Buy |
13,195
+1,195
| +10% | +$9.69K | 0.01% | 677 |
|
|
2015
Q4 | $97K | Buy |
12,000
+1,000
| +9% | +$8.08K | 0.02% | 768 |
|
|
2015
Q3 | $92K | Buy |
11,000
+2,600
| +31% | +$21.7K | 0.01% | 794 |
|
|
2015
Q2 | $78K | Buy |
8,400
+7,400
| +740% | +$68.7K | 0.01% | 909 |
|
|
2015
Q1 | $10K | Sell |
1,000
-600
| -38% | -$6K | ﹤0.01% | 1746 |
|
|
2014
Q4 | $18K | Buy |
+1,600
| New | +$18K | ﹤0.01% | 1655 |
|